WO1999037820A1 - Methode d'amplification exponentielle d'un acide nucleique utilisant une seule amorce de polarite opposee - Google Patents
Methode d'amplification exponentielle d'un acide nucleique utilisant une seule amorce de polarite opposee Download PDFInfo
- Publication number
- WO1999037820A1 WO1999037820A1 PCT/US1999/000834 US9900834W WO9937820A1 WO 1999037820 A1 WO1999037820 A1 WO 1999037820A1 US 9900834 W US9900834 W US 9900834W WO 9937820 A1 WO9937820 A1 WO 9937820A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- primer
- target
- amplification
- region
- Prior art date
Links
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 117
- 230000003321 amplification Effects 0.000 claims abstract description 114
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 69
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 48
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims description 39
- 108020004414 DNA Proteins 0.000 claims description 33
- 108091034117 Oligonucleotide Proteins 0.000 claims description 26
- 230000000295 complement effect Effects 0.000 claims description 20
- 108060004795 Methyltransferase Proteins 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 9
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 230000002255 enzymatic effect Effects 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 108700001094 Plant Genes Proteins 0.000 claims description 3
- 244000037640 animal pathogen Species 0.000 claims description 3
- 244000000003 plant pathogen Species 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 238000003505 heat denaturation Methods 0.000 claims description 2
- 239000013615 primer Substances 0.000 description 122
- 239000000047 product Substances 0.000 description 59
- 238000006243 chemical reaction Methods 0.000 description 37
- 230000000694 effects Effects 0.000 description 16
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000872 buffer Substances 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 241000894007 species Species 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229960002685 biotin Drugs 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 7
- 239000011616 biotin Substances 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 102100034343 Integrase Human genes 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000037230 mobility Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010058432 Chaperonin 60 Proteins 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000003196 chaotropic effect Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- -1 nucleotide phosphoramidites Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108010037497 3'-nucleotidase Proteins 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108700030911 E coli dnaB Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 101150104269 RT gene Proteins 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940064734 aminobenzoate Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000001036 exonucleolytic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000012409 standard PCR amplification Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Definitions
- This invention relates to the amplification of nucleic acid using single nucleic acid primer having two 3' ends.
- the present invention describes a novel nucleic acid amplification method utilizing a unique primer structure referred to as a single opposing polarity primer.
- nucleic acid amplification technologies are now available. This method is distinct in that only a single primer addition is required for amplification.
- This new primer structure can be synthesized on a standard nucleic acid synthesizer using commercially available reagents.
- use of the single opposing polarity primer has the advantages that only a single primer need be added to the amplification mix, that since the single primer has two sequence specificities these are added to the reaction in perfect balance, that the unique dual 3' end of the primer avoids 5' exonucleolytic degradation, and that the amplification products all have perfectly single stranded tails that may aid in product detection by hybridization. 2
- This invention provides for a method for amplification of a target nucleic acid sequence using 3' enzymatic extension and a single amplification primer.
- the method comprises the steps of: (a) contacting in an aqueous solution the target nucleic acid having three defined regions said regions being a 5' P region, an intervening S region and a 3' Q region with an oligonucleotide primer comprising two 3' ends connected through a bond or linking composition wherein the first 3' end, 3P-1 is able to hybridize to the 3' Q region of the target nucleic acid sequence and the second 3' end 3P-2 is able to hybridize to the complement of the 5 'P end of the target oligonucleotide sequence; and, (b) further contacting the solution of step i with a DNA polymerase that carryouts 3 ' DNA extension wherein said contacting is (a) under conditions in which the primer is able to hybridize to either the complement of the 3'Q region or the 5
- the copy is separated from the template target sequence, the primer hybridized to both the original target and the 3' extension copy and additional copies of the S region synthesized by 3' extension of the primers using DNA polymerase. Separation may be achieved by heat denaturation or by a helicase enzyme.
- a preferred polymerase is thermostable as it resists denaturation under temperatures required to denature duplexed nucleic acid.
- the target nucleic acid may be a double stranded DNA.
- the amplification method can use a primer wherein the 3'P-l and 3'P-2 are linked by nucleotides.
- the method can also include an amplification primer is covalently linked to a detectable reporter.
- the method of this invention can involve target nucleic acid that is diagnostic of an animal or plant pathogen and where the target nucleic acid is an animal or plant gene.
- nucleic acid amplification primers comprising nucleic acid sequences having two 3 ' ends where both ends complement different nucleic acid sequences of a target double stranded nucleic acid sequence where the target has three defined regions: a 5' P region, an intervening S region and a 3' Q region; 3 wherein the primer has a first 3' end, 3P-1 which is able to hybridize to the 3'Q sequence of the target nucleic acid sequence and a second 3' end, 3P-2 which is able to hybridize to the complement of a 5'P end of the target oligonucleotide sequence.
- the primers can be directed to any type of target and be labelled as described above in the method provided herein.
- aqueous solutions comprising the nucleic acid amplification primers described herein.
- the solution can also comprise the amplification reaction components described above such as thermostable DNA polymerases, helicase enzymes and assorted target nucleic acids including genes of any sort and pathogens that need to be diagnosed in medical or agricultural applications.
- Fig. 1 is a schematic representation of the amplification system.
- Fig. 2 is a single primer of opposing polarity exponential amplification of the E. coli GroEL gene.
- Fig. 3 is a single primer of opposing polarity exponential amplification of the HIV RT gene.
- amplification refers to the duplication of a target nucleic acid while in its broadest context the term includes a single duplication, optimum use of the invention involves a series of repetitive steps that result in exponential duplication of a target nucleic acid.
- complement refers to a strand of nucleic acid which is hybridized to, or which has the ability to hybridize to a reference strand of nucleic acid.
- An exact complement indicates that the every base in the reference strand matches the bases in the hybridizing strand with which it can form hydrogen bonds.
- An inexact complement means that at least one mismatched base is present between the reference strand and the hybridizing strand.
- covalently linked refers to a bond between two distinct molecular species that is the result of shared electrons between constituent atoms of each species.
- detectable reporter refers to a molecular species which can be identified based on either enzymatic activity or by chemical properties, and which may be used to identify a successful hybridization reaction.
- an oligonucleotide may be radiolabeled which can be measured by autoradiography or scintillation counting.
- Horseradish peroxidase is commonly used to identify hybridization when conjugated to a signal oligonucleotide either covalently or though a biotin residue.
- diagnosis refers to a kit or a process which is used in identification of a specific nucleic acid sequence.
- “Diagnostic” typically refers to medical and veterinary applications in which a disease causing species is being detected. In a broader sense, “diagnostic” may be referred to forensic or food applications in which specific nucleic acid sequences can refer to either contaminating food pathogens, adulteration with undesired food fillers, or for specific sequences used to identify an individual in forensic applications.
- Another form of medical "diagnostic” may refer to a test for a specific DNA sequence associated with a genetic disease, or a predisposition to a disease state such as cancer.
- hybridize refers to a process by which two single nucleic acid strands interact and form a stable or quasi-stable double stranded helical structure.
- the two strands interact via hydrogen bonding between bases on opposing strands, with adenosine forming a hydrogen bond with either thymidine in DNA or uracil in RNA, and guanosine forming a hydrogen bond with cytosine.
- nucleic acid refers to either double or single stranded DNA or RNA.
- polarity refers to the directionality of the information encoded on a strand of nucleic acid. Nucleic acids are generally represented and read in the 5' to 3' direction. When representing a double-stranded nucleic acid, the upper strand is generally drawn as 5' to 3' while the lower complementary strand is drawn 3' to 5' .
- opposite polarity refers to a switch in the natural polarity of a nucleic acid strand within a contiguous sequence. For example, a single DNA strand has polarity written as 5' to 3'. Therefore, the natural direction of reading this strand would be 5' to 3', or left to right. If a second segment of DNA could be read from the 5' to 3' direction from right to left (with the 3' end of the primer to the left), then even though the polarity is the same for both segments (5' to 3'), the polarities point outwards from a common 5' end of attachment in opposing directions. 5
- single amplification primer refers to a single molecular species which can bind to a target nucleic acid template sequence and directs the synthesis of a new nucleic acid strand complementary to the template strand.
- target refers to any nucleic acid species which may hybridize with the single opposing polarity primer and which can be copied by a polymerase activity.
- 3' enzymatic extension refers to an activity carried out by a polymerase molecule in the addition of nucleotides to the 3 ' end of a nucleic acid molecule.
- thermoostable DNA polymerase refers to an enzymatic activity that can be isolated from a number of bacterial or ' mammalian sources which exhibits the ability maintain enzymatic activity in response to repeated cycles of heating and cooling.
- the present invention relates to a new method for the amplification of nucleic acid sequences utilizing a single primer of unique structure.
- This amplification method is expected to have broad applicability in the areas of genetic research, diagnostics, and forensics. Methods for the production of the single amplification primer, reaction conditions, and diagnostic kits are described. Many techniques for the amplification of nucleic acid sequences have been described. The best known is the Polymerase Chain Reaction (or PCR). Others include the Ligase Chain Reaction, transcription based nucleic acid amplification such as NASBA, and single primer amplification systems such as SPA. PCR and LCR both require temperature cycling to cause nucleic acid amplification, while NASBA is an isothermal reaction.
- nucleic acids have strand polarity. That is, sequences are directional defined by the chemical bond formed between adjacent bases within the nucleic acid strand. Thus, the 5' carbon of the sugar moiety of each nucleotide is linked to the 3' carbon of the sugar moiety in the adjacent nucleoside. Therefore, every natural nucleic acid strand has both a 5' and a 3' end.
- the upper strand usually is drawn in the 5' to 3' direction.
- the lower complementary strand would have the opposite polarity, or 3' to 5' .
- All polymerases 6 require a free 3' hydroxyl group onto which nucleotides are added.
- oligonucleotides are synthesized having a single 5' to 3' polarity. Therefore, for an amplification reaction such as PCR, two oligonucleotides must be synthesized, each complementary to the opposite strands.
- a novel aspect of this invention is that this amplification method requires only a single primer having two 3' ends.
- the single primer contains two sequence specificities defining the region of the target which is to be amplified. The two sequence specificities are arranged in opposite polarities and joined through their 5' ends as shown below:
- this structure Since this structure has two 3' ends, it does not have a classical oligonucleotide structure which would normally have a single polarity sequence running 5' to 3'.
- the bond between both sequence specificities can be directly through a phosphodiester linkage, or may be through other spacer arms of varying length.
- the spacer arm itself may have functional groups useful in the analysis of the amplification products.
- each sequence specificity may contain detectable groups such as biotin. Sequences may also be introduced that would allow cloning of amplification products, or production of RNA transcripts corresponding to the amplified product.
- the use of the single primer in an amplification reaction is shown in Figure 1. Because the single primer contains both sequence specificities, only one addition of this primer is required for amplification.
- the template strand is denatured so that the primer may hybridize to its complement.
- the 3' end of the primer is then extended by a polymerase activity forming the complementary strand.
- the two strands are once again denatured allowing binding of the second sequence specificity of the single primer.
- the 3' end can then be extended once again by the polymerase activity to complete the second strand.
- the product of one round of amplification will then have single strand tails.
- this amplification system might not yield discrete products, but rather a smear of concatameric products. This is because the product of the amplification has functional priming sequences on it's ends which can bind to both template strands yielding amplification products joined through the opposing primer. Multiple cycles would then lead to concatameric products of increasing length. This potential problem may be exacerbated in the later amplification cycles when the product template concentration is much higher, and the primer concentration is lower which would encourage product primer binding to both template strands. The data presented below demonstrates that this does not happen, or if it does happen, it constitutes a very minor secondary reaction. In fact, very discrete amplification products were obtained.
- the presence of the second sequence specificity with opposite polarity does not interfere with the hybridization of the first sequence specificity.
- the use of the single opposing polarity primer is demonstrated using temperature cycling to effect strand denaturation.
- any method to cause strand separation can be utilized including chemical methods and enzymatic activities such as that derived from helicase proteins.
- RNA polymerase recognition sequences can likewise be incorporated into the primer for the generation of RNA transcripts form the amplification product.
- the RNA polymerase binding site is generally 20 - 30 bases long.
- RNA transcripts prepared this way are convenient research tools, or can be used to prepare controls for diagnostic kits.
- Some additional features of the amplification system described in this application include the following. For diagnostic assays, only a single primer addition is required, which has built in both sequence specificities in a perfect balance. Also, some thermostable polymerases do have 5' - 3' nuclease activity which can result in the removal of 5' terminal groups, an activity which would be avoided in this system. In addition, products of the single primer amplification have single stranded tails on completed products which may be useful in hybridization detection of the reaction products.
- the single opposing polarity primer may easily be prepared on a standard DNA synthesizer.
- 3' nucleotide phosphoramidites are added to the 3' most base of the sequence being synthesized in a step-wise fashion.
- 5' phosphoramidites are also available which can be added on the synthesizer in the opposite direction. Therefore, one would synthesize the first sequence specificity using the standard 3' nucleotide phosphoramidites. When the 5' end of that sequence is reached, the 5' phophoramidites are then added to complete the second sequence specificity.
- a second method would be chemical linkage of two oligonucleotides with
- Modifying reagents could be bifunctional or homofunctional.
- the first oligonucleotide could be synthesized directly having a 5' sulfhydryl group.
- the second oligonucleotide could be synthesized having a 5' amine group.
- the 5' amine could be modified to a sulfhydryl specific 5' iodo- group using the bifunctional cross-linking agent Succinimidyl(4-iodoacetyl) Amino Benzoate (SIAB).
- the sulfhydryl and iodo- modified oligonucleotides could be mixed and allowed to react. It would then be necessary to purify the opposing polarity primer from the reaction mix by HPLC, size exclusion chromatography, or gel electrophoresis. Homofunctional cross-linking reagents could likewise be used. For example, the first oligonucleotide could be reacted with a large excess of the reagent cyanuric chloride. Since the reaction products will include 9 oligonucleotide dimers, the reaction mix would be purified by HPLC. Singly modified oligonucleotide would then be mixed with the second oligonucleotide containing a 5 ' reactive group. The single opposing polarity primer would then be purified as above.
- Bacterial samples are collected by centrifugation. Bacteria are protease digested and then lysed with SDS. The lysate is extracted 1 - 2X with buffer saturated phenol. Total nucleic acids are then precipitated with 2.5 vol. ethanol. The nucleic acid preparation can be stored at this point at -20 C. Alternatively, the nucleic acid may be collected by centrifugation and resuspended in buffer or water. The nucleic acid is stored at 4 C. ii. Eukaryotic DNA Common samples include blood and cell culture samples. In the case of blood, density centrifugation is first used to obtain a purified white cell population. Cells are suspended in a buffer containing 1 % Tween 20.
- DNA is then prepared by protease digestion of the nuclei, lysis with SDS, phenol extraction, and preferably dialysis of the very high molecular weight DNA.
- the DNA may be collected by ethanol precipitation.
- DNA is stored under ethanol at -20 C, or suspended in water or buffer at 4 C.
- iii. Eukaryotic RNA Cells are suspended in highly concentrated guanidine thiocyanate. Highly purified RNA is prepared by layering the lysate over a cesium chloride cushion and spinning the sample in an ultracentrifuge overnight at high speed. RNA will form a pellet under the cesium layer while DNA will remain soluble. The RNA pellet is 10 collected and resuspended in water or buffer and stored at -70 C.
- RNA is selectively precipitated from the guanidine thiocyanate lysate with 0.5 vol. ethanol. The precipitate is collected by centrifugation and resuspended in water for storage at -70 C.
- Bacterial cells carrying plasmid DNA are collected by centrifugation.
- the cells are resuspended in buffer containing lysozyme. After digestion, the cells are lysed with an alkaline SDS solution which also denatures the bacterial genomic DNA and plasmid DNA.
- the suspension is then neutralized causing renaturation of the plasmid DNA and precipitation of the genomic DNA.
- the precipitate is removed by centrifugation, and the plasmid DNA in the supernatant is precipitated with ethanol.
- the plasmid DNA is suspended in water or buffer and then stored at -70 C.
- the dual opposing polarity primer is designed much like primers for other amplification systems.
- the length of each recognition sequence in the primer is chosen to be, but not limited to, a range of sizes from 15 to 30 bases.
- the preferred GC content is 50% but other compositions may be used as well.
- Modified bases such as those containing biotin or chemically reactive groups such as free primary amines may be incorporated into the primer.
- Sterile distilled water is added to the primer to make a final concentration of lOOuM.
- the concentrated primer solution is stored at -20 C. ii. Reaction Conditions
- a typical reaction will contain the single opposing polarity primer at a final concentration of 3uM, buffer salts, 20mM Tris-HCl (pH8.4), 50mM KC1, 2mM MgCl 2 , and 200uM dNTPs, the template, and the DNA polymerase. Amplification reactions are run using a standard DNA thermocycler.
- the magnesium concentration is critical for efficient amplification.
- the concentration must be above 1.5mM.
- 2mM is chosen as a sufficient concentration, but for certain templates and primers, it may be necessary to titrate the magnesium concentration to the optimum concentration.
- KC1 The amount of salt added to the reaction (KC1) maintains a sufficient ionic strength for 11 binding of the primer during amplification.
- salt concentrations above lOOmM may adversely affect the polymerase activity.
- concentration of the nucleotides must be relatively low (0.2mM). If the concentration is too high, misincorporation of nucleotides may result in sequence errors.
- the primer concentration must be controlled since if the concentration is too high, then mis-priming or non-specific priming may result.
- thermostable polymerase For the single opposing polarity primer amplification reaction, it is necessary to use a thermostable polymerase.
- thermostable polymerases A variety of thermostable polymerases are now available commercially including but not limited to Taq, Pfu, and Pwo. The amount of added polymerase can influence the specificity of the amplification reaction.
- Too much polymerase can lead to non-specific amplification, while too little will decrease the yield of product.
- 1 unit of Taq DNA polymerase is sufficient for specific amplification with good yield of product.
- the single opposing polarity primer When using the single opposing polarity primer to amplify a sequence from an RNA template, it is first necessary to copy the RNA strand into DNA utilizing a reverse transcriptase activity.
- a 20ul reaction mix contains 20mM Tris-HCl (pH8.4), 50mM KC1, 2mM MgCl 2 , and ImM dNTPs, at least luM single opposing polarity primer, template RNA, and sufficient reverse transcriptase activity.
- reverse transcriptases are commercially available. Commonly used is AMV reverse transcriptase or MMLV reverse transcriptase.
- the reverse transcription reaction is incubated for 1 hour at 42 C. Then, the reaction mix is diluted with water and buffer to maintain the salt concentration and primer concentration, while diluting the dNTPs to 0.2mM. The reaction is then processed by thermal cycling.
- the melting temperature in which the template is converted to single strands there are three segments to a typical thermal profile, the melting temperature in which the template is converted to single strands, the annealing temperature in which the primer will bind to the template, and the extension temperature, in which the polymerase has maximum activity for primer extension.
- the best thermal profile is determined empirically and is based on the sequence of each segment of the single opposing polarity primer. For example, from the sequence, one can determine the Tm of each segment of the primer. Then, the annealing temperature can be chosen as about 5 degrees below the Tm. The number of cycles is chosen based on the amount of input template, and the level of sensitivity required. 12 iii. Helicase Mediated Amplification
- An ideal use of the single opposing polarity primer is the design of an isothermal amplification system utilizing helicase activity to separate DNA strands instead of using heat.
- Helicase proteins separate double stranded DNA at the expense of hydrolysis of ATP.
- Helicase binds to the 3' end of single stranded DNA with high affinity and translocate down the strand.
- a number of helicase proteins have been identified and studied. It has been found that helicases oligomerize when they bind to a nucleic acid. Some, such as the E coli DnaB protein and the SV40 large T antigen, form hexamers when bound.
- a hexamer due to it's size would require a large binding site making these proteins less suitable for an amplification mediating protein.
- Some activities such as the SV40 T antigen also possess' an RNA helicase activity.
- Others such as the E. coli Rep protein, the E. coli UvrD protein, and the HeLa helicase form dimers which require much smaller binding sites. The mechanism of action of some of these proteins has been studied in detail.
- the Rep helicase isolated from E. coli has been shown to be able to "jump" polarities, a situation that would be encountered using the opposing polarity primer.
- thermostable helicase protein which can be isolated from a number of thermophylic bacteria. Possible sources are Thermus aquaticus and certain Thermophillus species. This would allow the amplification to be done at higher temperature which would increase the specificity of primer binding. iv. Detection of Amplification Products Amplification products can be detected by a number of methods. The simplest is by analyzing a portion of the amplification product by gel electrophoresis.
- Nonspecific amplification products would appear as bands of weaker intensity at varying mobilities from the specific product.
- Gel electrophoresis is particularly convenient when amplification conditions are being developed, since it is relatively easy to determine the specificity of the amplification by the yield of specific product and lack of spurious products.
- Amplification products from the single opposing polarity primer amplification reaction have slightly slower mobilities than amplification products without the single 13 strand tails.
- a convenient method is based on forming a sandwich between the amplification product, a capture oligonucleotide linked to a solid phase, and a specific signal oligonucleotide.
- the signal oligonucleotide may contain a reporter group which will be recognized by a binding molecule conjugated to an enzymatic activity.
- the signal oligonucleotide may have a biotin group which would be recognized by a streptavidin-horseradish peroxidase conjugate.
- a signal oligonucleotide may not be needed if the amplification product is labeled with biotin during the amplification, or if the primer itself is labeled with biotin. In either event, the presence of a successful amplification can be determined by incubating the solid phase in contact with a colorimetric substrate and measuring the amount of color generated.
- the hybridizations may be carried out at elevated temperatures, or in the presence of chaotropic salts.
- Salt concentration and temperature combine to define the stringency of the hybridization.
- low salt concentration together with high temperature would be considered high stringency conditions.
- High stringency conditions would be used under conditions where an exact match between the capture probe and the amplification product is desired. For example, when differentiating between amplification products differing by a single base pair mismatch, high stringency is required.
- Low or relaxed stringency conditions consists of high salt and lower temperatures. These conditions would allow hybridization analysis of identical genes between closely related species.
- stringency may be controlled by either high concentrations of chaotrope (high stringency), or low concentrations of chaotrope (low stringency).
- the single opposing polarity primer amplification products may offer an advantage when only detection of a single species is desired. This is due to the single strand tails present on the amplification products.
- the amplification product may be labeled with biotin during the amplification reaction. Then, either the 14 complement of the sequence of either tail may be used to capture the amplification product. Since the tails are always single stranded, the lack of strand competition should result in a very sensitive detection step.
- the single opposing polarity primer amplification reaction is best used in the design of diagnostic kits.
- the primer could be supplied in such a kit in either of two forms, as a separate reagent to be added to a reaction mix for amplification of a specified target, or in an optimized reaction buffer ready to be added to a sample with only addition of the enzyme being otherwise required.
- a kit for the detection of E. coli would contain: 1. 2X reaction mix containing a buffer component, the single primer, magnesium salts, and deoxynucleotide triphosphates. This reagent may be supplied pre-dispensed in appropriate tubes ready to use 2. Sterile water to dilute the sample 3. Thermostable polymerase which may be part of the 2X reaction mix 4. Detection reagents consisting of capture oligonucleotides in a preadjusted buffer, and a reagent plate containing the remainder of the sandwich hybridization reagents.
- PCR has been used to detect E. coli using two primers directed towards the GroEL gene.
- the primers have the following sequences
- a single primer was synthesized having the sequence
- the reaction conditions were in lOOul total volume 20mM Tris-HCl (pH8.4), 50mM KC1, 2mM MgCl 2 , and 200uM dNTPs.
- each of the two primers was added to a final concentration of luM.
- the amount of added primer was varied.
- Each reaction was run using 1 unit of Taq polymerase (Life Technologies) and lug of DNA. Samples were overlayed with mineral oil and thermocycled using the following program: lmin. at 94°C, 1 min at 50°C, 1 min at 72°C for 35 cycles, a 5 min final extension at 72°C, and a 4°C soak. The results of the experiment are presented in Fig. 2.
- a control tube is run without the addition of template to assess the presence- of background amplification.
- the PCR products using two oligonucleotide primers yields a single band as expected when the template DNA is included in the reaction mix. Without template, no product is obtained.
- the single primer reaction yields a single amplification product that migrates more slowly than the PCR product. This is due to the presence of the single strand tails on the single primer amplification products. The yield of product is dependent on the input amount of the single opposing polarity primer.
- Detection of HIV sequences was accomplished using primers directed towards the reverse transcriptase gene. Primers were prepared for a standard PCR amplification, as well as a single primer for the method used in this application. The sequences are: 16
- a single primer was synthesized having the sequence
- the reaction conditions were in 50ul total volume 20mM Tris-HCl
- the "S” refers to the single primer amplification
- the “D” refers to the single opposing polarity primer (or "double primer") amplification.
- the single opposing polarity primer amplification product has a slower mobility than the corresponding PCR product.
- the double primer system is more sensitive than the single primer system.
- the single primer system is less sensitive than the double primer.
- the sensitivities of both systems are comparable.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU22285/99A AU2228599A (en) | 1998-01-26 | 1999-01-13 | An exponential nucleic acid amplification method using a single primer of opposing polarity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7250298P | 1998-01-26 | 1998-01-26 | |
US60/072,502 | 1998-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999037820A1 true WO1999037820A1 (fr) | 1999-07-29 |
Family
ID=22108010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/000834 WO1999037820A1 (fr) | 1998-01-26 | 1999-01-13 | Methode d'amplification exponentielle d'un acide nucleique utilisant une seule amorce de polarite opposee |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2228599A (fr) |
WO (1) | WO1999037820A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004027025A3 (fr) * | 2002-09-20 | 2004-07-08 | New England Biolabs Inc | Amplification dependant de l'helicase des acides nucleiques |
US7662594B2 (en) | 2002-09-20 | 2010-02-16 | New England Biolabs, Inc. | Helicase-dependent amplification of RNA |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5043272A (en) * | 1989-04-27 | 1991-08-27 | Life Technologies, Incorporated | Amplification of nucleic acid sequences using oligonucleotides of random sequence as primers |
US5508178A (en) * | 1989-01-19 | 1996-04-16 | Rose; Samuel | Nucleic acid amplification using single primer |
US5610017A (en) * | 1991-12-11 | 1997-03-11 | Igen, Inc. | Method for conducting a polymerase chain reaction using an improved electrochemiluminescent label |
US5612199A (en) * | 1991-10-11 | 1997-03-18 | Behringwerke Ag | Method for producing a polynucleotide for use in single primer amplification |
-
1999
- 1999-01-13 WO PCT/US1999/000834 patent/WO1999037820A1/fr active Application Filing
- 1999-01-13 AU AU22285/99A patent/AU2228599A/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683202B1 (fr) * | 1985-03-28 | 1990-11-27 | Cetus Corp | |
US5508178A (en) * | 1989-01-19 | 1996-04-16 | Rose; Samuel | Nucleic acid amplification using single primer |
US5043272A (en) * | 1989-04-27 | 1991-08-27 | Life Technologies, Incorporated | Amplification of nucleic acid sequences using oligonucleotides of random sequence as primers |
US5612199A (en) * | 1991-10-11 | 1997-03-18 | Behringwerke Ag | Method for producing a polynucleotide for use in single primer amplification |
US5610017A (en) * | 1991-12-11 | 1997-03-11 | Igen, Inc. | Method for conducting a polymerase chain reaction using an improved electrochemiluminescent label |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004027025A3 (fr) * | 2002-09-20 | 2004-07-08 | New England Biolabs Inc | Amplification dependant de l'helicase des acides nucleiques |
JP2006500028A (ja) * | 2002-09-20 | 2006-01-05 | ニュー・イングランド・バイオラブズ・インコーポレイティッド | 核酸のヘリカーゼ依存性増幅 |
US7282328B2 (en) | 2002-09-20 | 2007-10-16 | New England Biolabs, Inc. | Helicase dependent amplification of nucleic acids |
AU2003272438B2 (en) * | 2002-09-20 | 2009-04-02 | New England Biolabs, Inc. | Helicase dependent amplification of nucleic acids |
US7662594B2 (en) | 2002-09-20 | 2010-02-16 | New England Biolabs, Inc. | Helicase-dependent amplification of RNA |
US7829284B2 (en) | 2002-09-20 | 2010-11-09 | New England Biolabs, Inc. | Helicase-dependent amplification of nucleic acids |
Also Published As
Publication number | Publication date |
---|---|
AU2228599A (en) | 1999-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3080178B2 (ja) | 核酸配列の増幅方法およびそのための試薬キット | |
EP0310229B1 (fr) | Amplification sélective de séquences de cible oligonucléotide | |
JP3360977B2 (ja) | 核酸の高感度検出方法 | |
US5578467A (en) | Use of deoxyinosine containing primers to balance primer efficiency in the amplification of nucleic acid molecules | |
DK2365078T3 (en) | Methods using the dual specificity oligonucleotide and dual specificity oligonucleotide | |
AU624601B2 (en) | Amplification and detection of nucleic acid sequences | |
JP4436039B2 (ja) | 増幅反応を多重化するための方法および装置 | |
JP2807202B2 (ja) | 核酸の高感度検出方法 | |
EP1184466A2 (fr) | Enrichissiment et amplification des cibles d'acide nucleique pour l'analyse dans un réseau | |
JP4263612B2 (ja) | アニーリング調節プライマーおよびその使用 | |
JP2000505312A (ja) | 標的核酸配列増幅 | |
JP5938348B2 (ja) | 反応特異性の増加のための非標準塩基を含む増幅プライマー | |
JPH05244996A (ja) | 変異核酸の検出方法 | |
AU3586693A (en) | Method for use of branched nucleic acid probes | |
AU2002329104A1 (en) | Annealing control primer and its uses | |
JP2005511096A6 (ja) | アニーリング調節プライマーおよびその使用 | |
US5550039A (en) | Oligonucleotide primers for HLA class I B locus DNA typing | |
EP3252168B1 (fr) | Amorce pcr liée à une séquence nucléotidique complémentaire ou à une séquence nucléotidique complémentaire comprenant des nucléotides incompatibles et procédé pour l'amplification d'acide nucléique la faisant intervenir | |
WO2007130967A2 (fr) | Nouvelles amorces oligonucléotides et procédé de réplication d'adn | |
US7501254B2 (en) | Methods and compositions for amplification and capture of nucleic acid sequences | |
US9657337B2 (en) | Reaction buffer for microarray | |
WO2005064020B1 (fr) | Analyse multiplex d'acides nucleiques a specificite elevee | |
WO1999037820A1 (fr) | Methode d'amplification exponentielle d'un acide nucleique utilisant une seule amorce de polarite opposee | |
JP2021505199A (ja) | 鋳型切り換え機構を通じて核酸ライブラリを調製するためのシステムと方法 | |
JPH10505230A (ja) | 修飾ヌクレオシドを用いての核酸の増幅方法及び抗体を用いての増幅生成物の検出 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |